The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma

4Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: This study aimed to study the diagnostic efficacy of positron emission tomography (PET)/magnetic resonance imaging (MRI), computed tomography (CT) and clinical metabolic parameters in predicting the histological classification of lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC). Methods: PET/MRI, CT and clinical metabolic data of 80 patients with lung ADC or SCC were retrospectively collected. According to the pathological results from surgery or fiberscopy, the patients were diagnosed with lung ADC (47 cases) or SCC (33 cases). All 80 patients were divided into a training group (64 cases), an internal testing group (8 cases) and an external testing group (8 cases) in the ratio of 8:1:1. Nine models were constructed by integrating features from different modalities. The Gaussian classifier was used to differentiate ADC and SCC. The prediction ability was evaluated using the receiver operating characteristic curve. The area under the curve (AUC) of the models was compared using Delong’s test. Based on the best composite model, a nomogram was established and evaluated with a calibration curve, decision curve and clinical impact curve. Results: The composite model (PET/MRI + CT + Clinical) owned the highest AUC values in the training, internal testing and external testing sets, respectively. In the training set, significant differences in the AUC were found between the composite model and other models except for the PET/MRI + CT model. The calibration curves showed good consistency between the predicted output and actual disease. The decision curve analysis and clinical impact curves demonstrated that the composite model increased the clinical net benefit for predicting lung cancer subtypes. Conclusion: The composite prediction model of PET/MRI + CT + Clinical better distinguished ADC from SCC pathological subtypes preoperatively and achieved clinical benefits, thus providing an accurate clinical diagnosis.

References Powered by Scopus

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

75699Citations
N/AReaders
Get full text

Radiomics: Extracting more information from medical images using advanced feature analysis

4377Citations
N/AReaders
Get full text

Computational radiomics system to decode the radiographic phenotype

4287Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tumor microenvironment responsive nanozymes for multimodal imaging of tumors

20Citations
N/AReaders
Get full text

Current status and prospect of PET-related imaging radiomics in lung cancer

4Citations
N/AReaders
Get full text

PET radiomics for histologic subtype classification of non-small cell lung cancer: a systematic review and meta-analysis

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tang, X., Wu, J., Liang, J., Yuan, C., Shi, F., & Ding, Z. (2022). The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.991102

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

50%

Researcher 2

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Computer Science 2

33%

Business, Management and Accounting 1

17%

Save time finding and organizing research with Mendeley

Sign up for free